Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Familial hypercholesterolemia (FH) is associated with low-grade systemic inflammation, a key driver of premature atherosclerosis. We investigated the effects of inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) function on inflammatory state, endothelial dysfunction and cardiovascular...
Guardado en:
Autores principales: | Patrice Marques, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervás, Juan F. Ascaso, Laura Piqueras, José T. Real, Maria-Jesus Sanz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18b9bb9d7ffb44ad935d98f1e616d8cd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
por: Rana K, et al.
Publicado: (2019) -
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas CE, et al.
Publicado: (2020) -
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Chandni Bardolia, et al.
Publicado: (2021) -
Nuevas piezas en el puzzle de la aterogénesis
por: de la Maza C,M Pía, et al.
Publicado: (1999) -
Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells
por: Allicia Jack, et al.
Publicado: (2021)